Portfolio Company Xcellbio expands Labcorp Collaboration for Cell & Gene Therapies portfolioDynamk CapitalApril 21, 2022
Portfolio Company Lightspeed Microscopy, Inc. Rebrands to Reflect Expanded Offering and Vision Dynamk CapitalFebruary 3, 2022
Dynamk Capital Joins World-Class Syndicate of LS Investors Participating in Xcellbio’s $27.5 Series B Round Dynamk CapitalJanuary 19, 2022
Kayo announces Daniella Kranjac, Dynamk Capital as a Top 22 in ‘22: Women in Life Sciences Dynamk CapitalJanuary 4, 2022
Virica Biotech Raises Series A Financing and Expands Operations to Support Manufacturing of Viral Medicines Dynamk CapitalOctober 4, 2021
Envisagenics Raises Series A Financing to Scale Its AI-powered RNA Splicing Drug Discovery Platform portfolioDynamk CapitalSeptember 29, 2021
Vectron Biosolutions to Boost Protein Production Offering with Acquisition of Secretion Platform from T3S Technologies and $2.7M Series A Financing Round Dynamk CapitalJune 17, 2021
Lightspeed Microscopy, Inc. raises $4M in Series A Financing Round with Plans to Revolutionize Pathology portfolioDynamk CapitalJune 15, 2021
Dynamk Capital Announces Final Closing of its Life Science Industrials Fund Dynamk CapitalApril 27, 2021
Curi Bio Raises $6M Series A Financing Round for iPSC-derived Predictive Platforms portfolioDynamk CapitalMarch 18, 2021
Lucid Scientific Secures $3 Million in Series Seed Financing Led by Dynamk Capital Dynamk CapitalOctober 1, 2020
Dynamk featured in Pharma’s Almanac article on disruptive Organ-on-a-Chip Dynamk CapitalOctober 1, 2020
Dynamk Launches Industry Insights Newsletter: Quarterly Trends, Transactions & Headlines Dynamk CapitalJuly 13, 2020
